AR and prostate carcinoma: Deep targeted and whole-exome sequencing of ctDNA in metastatic castration-resistant prostate cancer patients for comparison of base-line and posttreatment showed that the dominant androgen receptor (AR) genotype continues to evolve during sequential lines of AR inhibition and drives acquired resistance [88].